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Abstract
Objective—Cancer incidence and mortality statistics provide limited insight regarding the cancer
survivor population and its needs. Cancer prevalence statistics enumerate cancer survivors—those
currently living with cancer. Commonly used limited-duration prevalence (LDP) methods yield
biased estimates of the number of survivors. National estimates may not allow sufficient
granularity to inform local survivorship programs. In this study, complete prevalence (CP)
methods are applied to actual North Carolina Central Cancer Registry (NCCCR) data to generate
better, more informative prevalence estimates than previous methods.
Methods—Data included all incident cases for 1995–2007 from the NCCCR and US Census
population data. SEER*Stat software was used to calculate 13-year LDP. ComPrev software was
used to estimate CP for each cancer site, gender, and race combination.
Results—CP methods estimated 362,810 survivors in North Carolina on January 1, 2008, 40%
more than LDP estimates of 258,556, with substantial racial, regional, and gender differences in
prevalence rankings of several cancers.
Conclusion—CP estimates are substantially higher than previous prevalence estimates. This
study found previously unrecognized racial, regional, and gender differences. State and local
programs may apply these methods using their own data to develop better, more detailed estimates
to improve planning for their specific survivor populations' needs.
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Introduction
With advances in early detection, treatment, and knowledge and management of late effects,
cancer is evolving from an acute to a chronic disease that can be successfully managed for
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many years [1, 2]. Over the past 15 years, an aging United States population and declining
cancer mortality rates have contributed to a simultaneous increase in the number of cancer
survivors to more than 11.7 million as of January 1, 2007 [3]. The trends in North Carolina
are similar [4]. Accordingly, addressing the needs of specific survivor populations is of
growing importance among cancer centers, cancer care providers, and patient support
programs; however, the traditional cancer surveillance metrics used by cancer programs and
registries—incidence and mortality—provide limited insight to inform programmatic and
population needs.
Understanding cancer prevalence—defined as “the number or percent of people alive on a
certain date in a population who previously had a diagnosis of the disease” [5]—helps
address this need for better guidance and provides additional information relevant to the
specific services that will be needed. Conceptually, obtaining this measure appears
straightforward—counting the number of survivors alive at any point in time. However,
unlike incidence and mortality, which can be counted in this way and are currently captured
by registries through population-based surveillance, prevalence must be estimated.
Obtaining accurate estimates of prevalence requires either broad sampling by survey-based
surveillance or calculations based on available registry data, neither of which is
straightforward. For example, with survey-based reporting, recall bias may lead to under- or
over-reporting of cancers, with certain subgroups of patients more likely to misreport their
cancer history, and accuracy of self-reporting varying by cancer site with sensitivity varying
from 54 to 96% when compared to registry data [6, 7]. With registry data, limited-duration
prevalence (LDP) has been a convenient and commonly used method, calculated based on
available data in the registry (e.g., 10-year LDP based on 10 years of available registry data).
However, this simple measure often grossly underestimates actual prevalence for registries
that have been operational for fewer years, registries covering older populations, and cancers
that have longer survival periods. In these instances, the shorter-lived registries have
captured data over a shorter surveillance period than longer-lived ones. As a result, there is a
greater likelihood of individuals having had a cancer diagnosis prior to the registry opening
for older populations or cancers with long survival periods, thus contributing to biased
estimates when calculating limited-duration prevalence [8].
Developments in cancer surveillance methodology provide guidance for states and programs
to use their own data and calculate complete prevalence (CP) statistics, which help correct
for these sources of bias when estimating cancer prevalence in a population [8, 9]. For state
and local cancer registries and programs, calculating CP based on their own data can provide
important metrics to inform state and local programs to help them prioritize goals,
coordinate efforts, and allocate resources for cancer control and survivorship planning.
Calculating CP is an alternative to relying on prevalence estimates derived from other
sources of data such as the Surveillance, Epidemiology, and End Results (SEER) program
[10], which can be problematic due to both limited granularity and reporting details that may
not address local programs' specific needs and infrequency of updating. This study uses
North Carolina Central Cancer Registry (NCCCR) data to estimate and compare LDP and
CP for North Carolina and provides a detailed model of how other states and programs may
do the same using their own central cancer registry data.
Methods
CP estimation uses three software programs developed by the National Cancer Institute—
SEER*Prep, SEER*Stat, and ComPrev [11, 12]. The methods for estimating CP are
explained in detail elsewhere [8, 9, 13–15]. Briefly, the method first uses SEER*Prep
software to format cancer registry data and then uses SEER*Stat software to estimate LDP.
The CompPrev software is then used to estimate the number of cases diagnosed prior to (and
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thus not explicitly captured by) the initiation of surveillance by the population-based
registry. Based on incidence and survival models originally developed using SEER registry
data, it calculates a completeness index reflecting the degree to which these registries' LDP
is complete for specific combinations of cancer sites, races, and genders. The actual LDP is
then divided by the appropriate completeness index to estimate CP. [16] This study applies
CP and LDP methods to actual incidence and mortality/survival data from the NCCCR,
which is not part of the SEER program. (Note to Editor: This IRB information was moved to
the Acknowledgments section of this manuscript.)
Data
A limited dataset was obtained from the NCCCR, including the following variables: case
unique identifier, cancer type (primary site, histology, and behavior), cancer sequence
number, year of birth, month of birth, year of diagnosis, month of diagnosis, vital status at
last follow-up, year of last follow-up, month of last follow-up, race, ethnicity, gender, and
county. These data reflect all incident cases of malignant cancer diagnosed from 1995
through 2007, currently the most complete year of NCCCR data, including current vital
status, which was obtained by linking the case information to the North Carolina Death
Files, Social Security Death Index, and the National Death Index. The NCCCR data were
formatted to SEER*Stat standards using SEER*Prep software [16]. The data from the
NCCCR were merged with North Carolina total population estimates for the same years
from the US Census Bureau's Population Estimates Program, obtained through the SEER
program [17, 18]. State population estimates used four expanded races (White, Black,
American Indian/Alaska Native, Asian/Pacific Islander) and single ages (0–85+).
Calculating limited-duration prevalence
We first used the SEER*Stat software to calculate 13-year LDP, the most extended period
possible for the NCCCR, as of January 1, 2008, for each cancer site, gender, and race
combination [11]. In the SEER*Stat program selection window, we used the count method
of prevalence estimation and selected the “First Primary in Database Only” for multiple
primary selection. In the table window, we selected “Age at Prevalence Date” as the row
display variable. An LDP matrix was generated and exported to a text file. “Crude
prevalence” was selected in the statistic window, and the options of “Remove All Thousands
Separators (Commas)” and “Remove Flags (Footnote), Prefix, and Suffix Characters” were
selected when creating the text file.
Calculating complete prevalence
We used ComPrev software to convert LDP into CP for each cancer site, gender, and race
combination [12]. We selected the mode of “Single Group | Compute Completeness from
Imported Limited-Duration Prevalence | Default Parameters Only.” The prevalence date was
set to be January 1, 2008 with duration of 13 years. “Single ages (0, 1, 2, 3,…, 85 +)” was
selected for the age group output. After choosing a combination of site, gender, and race, we
imported the corresponding text file from the LDP matrix as generated by SEER*Stat.
Because the race-specific CP index has not yet been developed for American Indians/Alaska
Natives, and Asian/Pacific Islanders, race-specific CP could not be estimated for these
populations that comprise approximately 1.1% of the state's cancer population. ComPrev
then calculated the CP for single ages and all White or Black patients, regardless of
ethnicity.
Examination of regional variation and gender and race-specific estimates
In regional analysis, North Carolina's one hundred counties were categorized into six
geographic regions corresponding to the North Carolina Comprehensive Cancer Program's
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(NCCCP) Cancer Partnership Regions (See Fig. 2). We added an additional restriction in the
selection window of SEER*Stat to calculate region-specific LDP. Regional prevalence rates
for January 1, 2008 were calculated using the average of census population estimates for
July 1, 2007 and July 1, 2008, as done previously [3]. We then ranked the most prevalent
cancer sites by the sum of prevalence counts of men and women.
Sensitivity analysis
Estimates were calculated and examined as 10-year LDP and 10-year CP, and 13-year LDP
and 13-year CP, using both NCCCR data and SEER-13 registry data. North Carolina
estimates were compared to published North Carolina-specific and national prevalence
estimates [3, 19, 20]. Race- and gender-specific estimates were estimated for 23 cancer
types, all other cancer types combined, and all cancers overall, and compared among all
sources for variation and stability of estimates among samples, focusing on consistency and
predictability of changes in estimates among methods, time-periods, and data sources for all
cancer types and sub-populations.
Results
Using NCCCR data, CP methods estimated 362,810 cancer survivors were living in North
Carolina as of January 1, 2008. This estimate is 40% greater than the 13-year LDP estimate
of 258,556 and is consistent with national prevalence rate estimates of 4%. [3, 21] LDP
estimates are comparable to extrapolated values from prior North Carolina estimates [19,
20]. Table 1 presents the count estimates of LDP and CP for the most common cancers in
North Carolina, listed according to common cancer registry reporting standards. The five
cancers of greatest prevalence were female breast, prostate, colon/rectum, melanoma, and
lung/bronchus, which comprise 62% of North Carolina cancer survivors. The rank order of
the 5 most prevalent cancers did not differ between CP and LDP estimates; however, CP
estimates were 32% greater than LDP estimates. The top ten cancers reflect 79% of cancer
survivors, and they vary slightly in rank order between CP and LDP estimates.
Figure 1 illustrates the differences in LDP (dark bars) and CP (light bars—additional cases
added by CP) for the ten most prevalent cancers in North Carolina, ranked in order of
descending LDP. Compared to cancers with typically short survival duration, cancers of
greater survival duration tended to have greater difference between LDP and CP estimates.
For example, pancreatic, liver, and lung cancers are associated with poor survival, and in
these data CP estimates exceed those of LDP by 12, 14, and 25%, respectively. By
comparison, cervical, testicular, and uterine cancers typically have very good survival, and
CP estimates exceed those of LDP in these data by 110, 100, and 83%, respectively.
The most prevalent cancers were examined by race and gender (see Table 2). Variation in
rank order was notable by race and gender for cancers ranked three through five. Cervical
cancer was ranked fifth for Black women, though fourteenth among all women. Notably,
LDP estimates rank cervical cancer fifth among Black women, though CP estimates rank it
third. For Whites, melanoma ranked third and lung/bronchus cancers ranked fifth for both
men and women. Lung/bronchus cancer was ranked higher for Blacks than Whites. Prostate
and breast cancers were by far the most prevalent cancers for men and women, respectively,
and colorectal cancer ranked second regardless of race or gender.
The most prevalent cancers were also examined by North Carolina Cancer Partnership
Region (See Table 3, Fig. 2). Differences in the rank order for the regions were similar to
those of the state overall for the four most prevalent cancers, though there were some
variations among those ranked five through ten (Table 1). Differences between LDP and CP
estimates for uterine cancer consistently pushed it up in rank; for example, it was elevated
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from rank 8 (LDP) to rank 5 (CP) in the central region. There was greater variation among
regional estimated prevalence rates, for which colorectal cancer is presented in Fig. 2. The
western and northeastern regions were estimated to have greater prevalence rates than
elsewhere in the state.
Discussion
The Institute of Medicine (IOM) Report, Lost in Transition: From Cancer Patient to Cancer
Survivor, and the Centers for Disease Control and Prevention's (CDC) Comprehensive
Cancer Control Program recommends that states should consider survivorship care in their
cancer control plans, including developing accurate estimates of cancer survivors, and
focusing on improving the quality of life for people who survive cancer [22–25]. To inform
local and statewide cancer survivorship research, coordination, and planning efforts, we
used data from the NCCCR and applied recently developed statistical methods to generate
cancer prevalence estimates that are more accurate than previous methods. Understanding
prevalence of cancer at the state, regional, and local level will help provide survivorship
programs with a better understanding of the size and composition of the survivor population,
so that may tailor their resources and activities to meet the needs of specific populations [2,
19, 22, 26]. This study provides specific guidance for how other Comprehensive Cancer
programs and states not included in the SEER Registries may use their own data to develop
similar estimates and statistics to inform their specific cancer control and survivorship
programs.
CP methods using NCCCR data provided an estimate of cancer prevalence that is 40%
greater than LDP, the previously standard method, demonstrating significant
underestimation of cancer prevalence using the prior methods. CP methods estimate that 4%
of North Carolinians are living with a prior diagnosis of cancer, an estimate that is consistent
with national estimates [3]. The relative burden presented by each cancer type parallels that
of prior North Carolina estimates using LDP methods [19, 20], though the estimates
calculated here reflect more current population characteristics and extend prior work in as
much as these methods may yield a more accurate measure of the true prevalence of cancer
both among individual cancer sites and overall. Breast, prostate, colorectal, melanoma, and
lung/bronchus were found to comprise 62% of prevalent cancer in North Carolina,
suggesting priority cancers for survivorship programs.
Consistent with our expectation, the greatest differences between CP and LDP estimates
were typically seen in less fatal cancers that are commonly diagnosed at a younger age. Not
following this pattern, the minimal differences between CP and LDP estimates for prostate
cancer were notable and are likely in part influenced by the unique nature of prostate cancer
and Prostate Specific Antigen (PSA) testing since the early 1990s. Prior to widespread
adoption of PSA testing in the early 1990s, prostate cancer was more commonly diagnosed
at a more advanced stage and at an older age. In the mid-1990s, observed prostate cancer
incidence increased substantially. Over time, age at diagnosis has dropped by approximately
5 years (from approximately 72 in the mid-1980s to 67, recently), diagnoses typically occur
at an earlier stage, and there has been a contemporaneous decline in mortality [27, 28]. In
this study, surveillance data began in 1995, and so all surveillance is in the modern PSA
testing era. Given that trends in these data follow the age and survival characteristics
experienced nationally, it is reasonable to expect that relatively few men diagnosed in the
pre-PSA testing era (i.e., at older age, with more advanced disease, and shorter survival)
were alive at the time of these prevalence estimates, compared to those diagnosed and
actually observed in the data. Thus, LDP is accounting for the majority of prevalent cases,
which were actually observed during the surveillance period, and CP's adjustment for those
who were not actually observed in the NCCCR data is limited. By contrast, testicular cancer
Carpenter et al. Page 5













is diagnosed among men who are much younger (average age 24), and has very high
survival rates that have changed little in the past 20 years [29]. Accordingly, as expected, CP
accounts for a greater proportion of the prevalence estimate, reflecting a larger proportion of
the population diagnosed prior to the observation period and still living.
Important for this discussion, the granularity and accuracy of these estimates are relevant for
survivorship planning in the context that survivorship is more than simply “survival.” That
is, survivorship is complex and specific, and entails much more than a measure of the
percentage of the population still alive following a diagnosis of cancer, frequently
represented as a single statistic reflecting the proportion of the population alive 5-year post-
diagnosis. Rather, the National Cancer Institute defines survivorship as “the physical,
psychosocial, and economic issues of cancer, from diagnosis until the end of life….
Survivorship includes issues related to the ability to get health care and follow-up treatment,
late effects of treatment, second cancers, and quality of life.” [30] To this end, these methods
and the statistics they produce may help inform Comprehensive Cancer programs and other
state policies aimed at addressing these goals, ranging from facilitating basic healthful
behaviors, to ensuring insurance coverage for survivor-specific needs, to more informed
advance-planning for long-term and end-of-life care. The goal of this examination is to
develop better estimates and a more accurate and complete characterization of the survivor
population and their burden, allowing state and local policies and programs to better meet
the population's needs all along the survivorship spectrum. The regional, gender-based, and
racial differences presented in this study's estimates demonstrate the importance of
understanding the details of each local/regional community's prevalent cancer population
when prioritizing local survivorship services for different cancer sites.
For example, this analysis helped identify racial and regional variations that have received
limited attention to date. It demonstrates that relying on LDP alone would result in a
significant underestimation of the relative burden of lung/bronchus cancer among Blacks,
and identifies cervical and uterine cancers ranked as the 3rd and 4th most prevalent among
Black women in North Carolina, whereas overall analysis in these data would only present
them as 8th and 14th. Many public health and health-care systems may prioritize or allocate
resources to the top 5 or top 10 priority cancers and, relying on other data sources alone,
these cancers for this population may otherwise have gone overlooked. North Carolina
health systems may look to the data in Table 3 and Fig. 2 to provide not only a ranking and
corresponding prioritization of the cancers of greatest prevalence in their service areas, but
also an estimate of the number of individuals with a history of each cancer and regional
differences at a cancer-specific level. These formats allow a better understanding of regional
differences with sufficient granularity to inform planning for cancer-specific survivorship,
cancer control, and resource allocation. For example, Fig. 2 focuses on colorectal cancer—
one of the cancers of greatest incidence and prevalence for both men and women—and may
suggest an evaluation of colorectal cancer screening resource adequacy, both for primary
prevention and to meet the needs for greater post-treatment surveillance screening in the
colorectal cancer population. In the longer-term, it may also provide a measure against
which to assess the effectiveness of local cancer control efforts. Moreover, other states may
reference the methods described here to use their own data to develop their own estimates,
systems for characterizing their state's needs and goals, and means of tracking progress
toward them.
The NCCCP has embraced the IOM's and CDC's guidance [22–24] and set corresponding
goals in support of its survivorship vision [31]. It can use these data as the basis for
understanding the survivor populations in North Carolina and coordinating efforts to support
them. The NCCCP and other programs can use these estimates not only to understand,
monitor, and improve services for the survivor populations, but also as a basis for further
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understanding pre-diagnosis and ongoing health-care needs. For example, the regional
variation in colorectal cancer prevalence rates may be partly explained by regional
differences in cancer aggressiveness, as well as the availability of colonoscopy or other
colorectal cancer screening services. It may be that in Central North Carolina, there is a
significantly higher use of colonoscopy, commonly less-aggressive disease, better general
health behaviors or greater use of general health-care services, and pre-cancerous lesions are
more likely to be detected and removed. This may contrast to the northeastern and western
regions of the state, which may use good health behaviors or general health services less,
have greater prevalence of aggressive disease, and are comparatively under-resourced,
historically.
There is no gold standard for measuring or estimating cancer prevalence; accordingly, it is
not possible to validate these estimates against the actual proportion of the population living
with the cancer. The CP methods used here have been validated and used as the basis of
several studies, though the CP index was developed using SEER registry data for White and
Black patients, and not applied in this context on fewer than 15 years of surveillance. While
the performance of these indices on non-SEER data of fewer than 15 years of observation
remains unknown, the stability, consistency, and parity of data with national estimates
demonstrated during the sensitivity analyses suggest the methods are valid and at the very
least substantially more accurate than previously used LDP estimates. Due to development
and availability of race-specific CP indices for only Whites and Blacks, CP for those of
other races (American Indian/Alaska Native, Asian/Pacific Islander) was not calculable, and
thus, overall CP estimates are systematically very slightly lower than actual prevalence
because of their exclusion. These groups reflect approximately 1.1% of the state's cancer
population, and local programs should carefully examine their population to ascertain the
effect that this under-reporting may have on their programs and populations, while ongoing
research develops a more comprehensive set of race-specific indices for these other groups.
While these findings were generally consistent with SEER regions, variation in sub-
population characteristics preclude direct comparability, and no nearby states data were
available to compare a “nearest neighbor.” Accounting for migration into and out of North
Carolina also presents a challenge. It is likely that these North Carolina estimates are
conservative, given the net population growth during the observation period and North
Carolina's popularity as a retirement state [32].
As we continue to gain more information about survivor populations, one future direction is
the use of CP estimates to measure and predict survivor burden by cancer type over time.
Understanding how resource needs might differ depending on cancer type and diagnosis
date would further inform our ability to provide necessary services for survivors. Pairing CP
estimates with data from other sources, such as the Behavioral Risk Factor Surveillance
System (BRFSS), may provide additional insight regarding the health status, health needs,
and specific opportunities for intervention to improve the quality and duration of life among
specific groups within the survivor population [25, 33]. As the NCCCR continues to add
new cases, increased duration of cancer registration will allow continued examination of the
validity of these methods and stability of these estimates at 15 years (LDP and CP), and
either independently or linked to other data resources, will extend their utility.
While additional research is necessary to continue improving prevalence measures and
validating them, this study demonstrates the value of understanding CP as it allows more
informed planning of health-related survivorship services and resource allocation at the
state, regional, and local levels. It illustrates the use of recent cancer surveillance methods
for converting LDP to CP using data from the NCCCR and provides a model for states and
programs to develop prevalence estimates with their own data to inform and tailor
interventions and services to meet the needs of their populations, rather than relying on
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estimates based on other registries and their populations, and the vagaries of their level of
reporting or reporting frequency.
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Top ten most prevalent cancers in North Carolina: 13-year Limited-Duration Prevalence
estimates, and additional cases estimated using Complete Prevalence, as of January 1, 2008.
Data include first cancer diagnosis only, and not multiple primaries. LDP limited-duration
prevalence; estimated number of cancer-specific prevalent cases as of January 1, 2008, CP
complete prevalence; estimated number of cases added by CP methods to overall prevalence
estimate. Top 10 cancers are presented in order of descending LDP
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Estimated complete prevalence rates of colorectal cancer, by North Carolina Cancer
partnership region, 1 January 2008
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Table 2
Comparison of 13-year limited-duration and complete prevalence of top 5 cancers by race and gender
Rank Black White
Site Site
LDP CP LDP CP
Men
1 Prostate Prostate
11,433 12,592 38,331 43,301
2 Colon/rectum Colon/rectum
2,220 2,815 10,863 14,341
3 Lung/bronchus Melanoma
982 1,158 9,405 14,052
4 Kidney Urinary bladder
807 1,064 7,172 9,753
5 Oral cavity Lung/bronchus
588 718 4,880 5,931
Top 5 total 16,030 18,347 70,651 87,378
All Cancer 20,291 23,808 98,197 125,192
Top 5% 79.0 77.1 71.9 69.8
Women
1 Breast Breast
10,287 14,097 50,381 72,785
2 Colon/rectum Colon/rectum
2,795 3,694 10,273 14,514
3 Corpus uteri Melanoma
1,019 1,335 8,375 13,908
4 Lung/bronchus Corpus uteri
797 931 6,777 12,289
5 Cervix uteri Lung/bronchus
730 2,130 5,064 6,040
Top 5 total 15,628 22,187 80,870 119,536
All Cancer 21,864 31,564 112,841 172,556
Top 5% 71.5 70.3 71.7 69.3
Numbers are in count prevalence; Top 5 cancer sites are ranked by their LDP
LDP limited-duration prevalence, CP complete prevalence, NH non-Hodgkin's
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